RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
Endovascular therapy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery.
Hyogo Medical University
Nishinomiya, Hyōgo, Japan
NOT_YET_RECRUITINGHyogo Medical University
Nishinomiya, Hyōgo, Japan
RECRUITINGAchievement of mRS scores of 0-2
Time frame: 90 days after randomization
Achievement of mRS scores of 0-1
Time frame: 90 days after randomization
mRS shift analysis
Time frame: 90 days after randomization
NIHSS improvement of 8 points or more
Time frame: 48 hours after randomization
QOL (EQ-5D-3L)
Time frame: 90 days after randomization
Symptomatic intracranial hemorrhage
Time frame: 48 hours after randomization
Any intracranial hemorrhage
Time frame: 48 hours after randomization
All cause death
Time frame: 90 days after randomization
Recurrence of cerebral infarction
Time frame: 90 days after randomization
Decompressive craniectomy
Time frame: 7 days after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.